Oncology · Phase II

Top sponsors

• First People's Hospital 261 programs
• Chinese Academy of 198 programs
• George Institute for 118 programs
• United Therapeutics Europe 112 programs
• Telethon Foundation 91 programs
• Takeda 79 programs
• Regeneron UK 71 programs
• MSD Merck Sharp 63 programs
• Ningbo Cancer Hospital 62 programs
• Anaxis Pharma 57 programs
• AstraZeneca 52 programs
• HOFFMANN-LA ROCHE 50 programs

1. Ipilimumab

   United Therapeutics Europe Ltd

   BCLC Stage B Hepatocellular Carcinoma

   phase 2 · mab · terminated

   1 trial →

2. Irinotecan

   Xiyuan Hospital of China Academy of Chinese Medical Sciences

   Small Cell Lung Cancer

   phase 2 · small molecule · active

   1 trial →

3. Irinotecan Liposome

   Xiyuan Hospital of China Academy of Chinese Medical Sciences

   Metastatic Colorectal Cancer

   phase 2 · small molecule · active

   1 trial →

4. Irofulven

   Allarity Therapeutics

   Metastatic Castration-Resistant Prostate Cancer Patients

   phase 2 · small molecule · completed

   1 trial →

5. Irosustat

   United Therapeutics Europe Ltd

   Breast Neoplasms

   phase 2 · small molecule · terminated

   1 trial →

6. Ivaltinostat

   CG Oncology

   Metastatic Pancreatic Adenocarcinoma

   phase 2 · small molecule · active

   1 trial →

7. Ivonescimab

   Summit Therapeutics

   Advanced Head and Neck Squamous Cell Carcinoma

   phase 2 · mab · active

   1 trial →

8. Ivonescimab

   Summit Therapeutics

   Stomach Cancer Stage IV

   phase 2 · small molecule · active

   1 trial →

9. Ivonescimab

   Summit Therapeutics

   Salivary Gland Cancer

   phase 2 · small molecule · active

   1 trial →

10. Ivonescimab

    Summit Therapeutics

    Non-Small Cell Lung Cancer

    phase 2 · small molecule · active

    3 trials →

11. Ivonescimab

    Summit Therapeutics

    Metastatic Esophageal Adenocarcinoma

    phase 2 · small molecule · active

    1 trial →

12. Ivonescimab

    Summit Therapeutics

    Lung Cancer (NSCLC)

    phase 2 · small molecule · active

    1 trial →

13. Ivonescimab

    Summit Therapeutics

    Leiomyosarcoma

    phase 2 · small molecule · active

    1 trial →

14. Ivonescimab

    Summit Therapeutics

    Metastatic Colorectal Cancer

    phase 2 · small molecule · active

    2 trials →

15. Ivonescimab

    Summit Therapeutics

    Endometrial Cancer

    phase 2 · small molecule · active

    1 trial →

16. Ivonescimab

    Summit Therapeutics

    Thymus Carcinoma

    phase 2 · mab · active

    1 trial →

17. Ivonescimab

    Summit Therapeutics

    Cutaneous Squamous Cell Carcinoma

    phase 2 · small molecule · active

    1 trial →

18. Ivonescimab

    Summit Therapeutics

    Biliary Tract Cancer

    phase 2 · small molecule · active

    1 trial →

19. Ivonescimab 10 mg/kg

    Summit Therapeutics

    Extensive Stage Lung Small Cell Cancer

    phase 2 · small molecule · active

    1 trial →

20. Ivonescimab 20 mg/kg

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma (NPC)

    phase 2 · small molecule · active

    1 trial →

21. Ivonescimab combined with TP

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 · small molecule · active

    1 trial →

22. Ivosidenib combined with venetoclax and azacitidine

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 · small molecule · active

    1 trial →

23. Ixabepilone Injection

    Allarity Therapeutics

    Metastatic Breast Cancer

    phase 2 · small molecule · terminated

    1 trial →

24. Ixazomib

    Takeda

    Triple-Negative Breast Cancer

    phase 2 · small molecule · terminated

    1 trial →

25. Ixazomib

    Takeda

    Leukemia

    phase 2 · small molecule · terminated

    1 trial →

26. Ixazomib

    Takeda

    Mantle Cell Lymphoma

    phase 2 · small molecule · active

    2 trials →

27. J1S-MC-JP04

    Eli Lilly Co.

    Ewings Sarcoma

    phase 2 · small molecule · active

    1 trial →

28. J2R-MC-YAAD

    Eli Lilly Co.

    Nausea, Drug-Related Side Effects and Adverse Reactions, Vomiting, Neoplasms

    phase 2 · small molecule · active

    1 trial →

29. JAB-21822

    Lacuna Pharma Pty Ltd

    advanced solid tumors with KRAS G12C mutation

    phase 2 · small molecule · active

    1 trial →

30. JCAR017

    Celgene Europe Limited

    Lymphoma, Non-Hodgkin

    phase 2 · small molecule · completed

    1 trial →

31. JDQ443

    Novartis Pharmaceuticals

    Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.

    phase 2 · small molecule · active

    1 trial →

32. JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Cervical cancer

    phase 2 · small molecule · active

    1 trial →

33. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Relapsed/Refractory Tumors

    phase 2 · small molecule · active

    1 trial →

34. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 2 · small molecule · active

    1 trial →

35. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Rectal

    phase 2 · small molecule · active

    1 trial →

36. JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    MMRd/MSI-H stage II-III endometrial cancer

    phase 2 · small molecule · active

    1 trial →

37. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 2 · small molecule · active

    1 trial →

38. JEMPERLI for HPV-negative Head and Neck Squa…

    Fondazione Telethon ETS

    HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 · small molecule · active

    1 trial →

39. JIN-A02

    INTENSITY THERAPEUTICS, INC.

    EGFR Mutant Advanced Non-small Cell Lung Cancer

    phase 2 · small molecule · active

    1 trial →

40. JMT108

    Shanghai University of Traditional Chinese Medicine

    Unresectable Locally Advanced or Metastatic Melanoma

    phase 2 · small molecule · active

    1 trial →

41. JNJ-73841937, JNJ-61186372

    Janssen-Cilag International N.V.

    Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 · small molecule · active

    1 trial →

42. JS004

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Limited Stage Small Cell Lung Cancer

    phase 2 · small molecule · active

    1 trial →

43. JZP598

    Jazz Pharmaceuticals Ireland Limited

    Patients with HER2-expressing solid tumors

    phase 2 · small molecule · active

    1 trial →

44. JZP598

    Ningbo Cancer Hospital

    Adult Patients with HER2-IHC3+ selected solid cancers (endometrial, colorectal, head & neck or sarcoma) or HER2 mutant non-small cell lung cancer.

    phase 2 · small molecule · active

    1 trial →

45. KB707

    Krystal Biotech Netherlands B.V.

    Cancer

    phase 2 · mab · active

    1 trial →

46. KB707

    Krystal Biotech Netherlands B.V.

    Lung Cancer, Non-small Cell

    phase 2 · mab · active

    1 trial →

47. KETOROLAC, PREGABALIN

    The George Institute

    Estrogen receptor-positive early breast cancer (ER + BC).

    phase 2 · small molecule · active

    1 trial →

48. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Cardiff Oncology

    Anal cancer

    phase 2 · small molecule · active

    1 trial →

Frequently asked questions